Bioforum will bring the real-world data solutions of Clinerion’s Patient Network Explorer platform to patients and physicians in Israel and Australia, accelerating the development of innovative medications and improving access to new treatments.
Bioforum is a data-focused Contract Research Organization (CRO), offering a wide range of consulting services, including medical writing, data management and bio-statistical support.
Bioforum will support Clinerion by leveraging its network to enlarge Clinerion’s outreach in Bioforum’s target markets of Israel and Australia. Bioforum will also identify potential customers for Clinerion’s services, which enable pharmaceutical trial sponsors to more accurately refine trial protocol criteria and then find and match their trials to sites and patients, accelerating the set-up phase of trials by months.
“We are extremely excited to launch this collaboration and are confident that together we can promote clinical research in our target markets. We are keen to introduce more medical centers to Clinerion’s advanced technology,” says Bioforum’s President & Co-Founder, Mr. Amir Malka.
“Patients in both Israel and Australia are underserved by clinical research at the moment,” says Ian Rentsch, CEO of Clinerion. “We are pleased to have Bioforum on board to support bringing our solutions to market.”
For more information go to www.clinerion.com
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.